FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name <b>and</b> Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [ APLS ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Machiels Alec					<del></del>	<u> </u>		<del>catroard,</del>	LICE LILE		:	X Directo	r		10% Ow	ner		
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC					3. Date of Earliest Transaction (Month/Day/Year) 01/01/2019							Officer below)	(give title		Other (s below)	pecify		
6400 WESTWIND WAY, SUITE A						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street) CRESTWOOD KY		Y	40014					·	•	,	Line	X Form fi	led by More		rting Persor One Repor			
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Transactior ate Ionth/Day/Yo	Execution Date,			Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		5. Amour Securitie Beneficia Owned F	s ally ollowing	Form:	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr				6. Date Exerc Expiration Da (Month/Day/Y	ite	7. Title and of Securiti Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock option (right to buy)	\$13.19	01/01/2019		A		17,580		(1)	12/31/2028	Common Stock	17,580	\$0.00	17,580		D			

## **Explanation of Responses:**

1. This option was granted on January 1, 2019 and will vest in four equal quarterly installments on April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020, subject to continued service as a director.

## Remarks:

/s/ David Watson, attorney-infact for Alec Machiels

01/03/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.